1 in 5 Adults Report Anxiety, Depression; New Esketamine Warning; Autism Dx Up 175%

(MedPage Today) -- One in five adults said they experienced any symptoms of anxiety or depression in a 2-week period, according to a 2022 CDC survey.
The FDA added a warning to the label of esketamine nasal spray (Spravato), noting that long-term...